EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 28 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $11,928,000 | -24.4% | 200,000 | 0.0% | 2.11% | -19.5% |
Q2 2017 | $15,778,000 | -4.9% | 200,000 | 0.0% | 2.62% | +8.6% |
Q1 2017 | $16,588,000 | -49.0% | 200,000 | -51.2% | 2.41% | -45.1% |
Q4 2016 | $32,529,000 | +1.9% | 410,000 | -10.1% | 4.38% | +24.6% |
Q3 2016 | $31,920,000 | +62.6% | 455,995 | -9.9% | 3.52% | +26.5% |
Q2 2016 | $19,628,000 | -3.1% | 505,995 | +1.2% | 2.78% | -8.8% |
Q1 2016 | $20,250,000 | -42.9% | 500,000 | +25.0% | 3.05% | -28.1% |
Q4 2015 | $35,468,000 | +59.7% | 400,000 | +33.3% | 4.24% | +19.6% |
Q3 2015 | $22,209,000 | -8.4% | 300,000 | 0.0% | 3.55% | +10.0% |
Q2 2015 | $24,258,000 | -19.2% | 300,000 | -58.1% | 3.22% | -30.5% |
Q1 2015 | $30,014,000 | +384.1% | 716,500 | +79.1% | 4.64% | +385.1% |
Q4 2014 | $6,200,000 | +22.5% | 400,000 | 0.0% | 0.96% | -8.2% |
Q3 2014 | $5,060,000 | -11.7% | 400,000 | 0.0% | 1.04% | -31.5% |
Q2 2014 | $5,732,000 | +12.4% | 400,000 | 0.0% | 1.52% | +29.5% |
Q1 2014 | $5,100,000 | – | 400,000 | – | 1.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |